Race for the vaccines is heating up. There have been many competitive moves over the past 6 months regarding vaccine candidates and the ongoing clinical trials. Moderna’s mRNA-1273, an mRNA vaccine candidate, was the first and most aggressive out of the gate. We’ve since seen the University of Oxford and AstraZeneca’s adenoviral-vector vaccine, codenamed ChAdOx1 seemingly perform quite well in its early trials. Johnson & Johnson and Janssen have been working feverishly on their candidate, codenamed Ad26.COV2.S, which is also an adenoviral-vector vaccine. Pfizer and BioNTech have similarly been working on a pair of mRNA vaccines, codenamed BNT162b1 and BNT162b2. These candidates represent several ‘shots-on-goal’ from some stellar scientists, and it’s likely that many, if not all, will eventually attain approval. Keep note, though, that mRNA vaccines don’t have regulatory precedent, so while the technology could absolutely revolutionize and simplify the philosophy of vaccination in the future, the FDA and other agencies haven’t approved one yet, and they need to acknowledge that internally amidst their review and approval processes. In addition to the coded vaccines above, there are over 30 other candidate vaccines in various stages of research, development, and trial staging. Many have been granted Fast Track Designation, so they should fully confound and bottleneck the Fast Track system. We will see how the Theory of Constraints works when Fast Track candidates are competing with other Fast Track candidates. Suffice to say, there will be no shortage of effective and safe vaccines available, however likely not until we’re into calendar year 2021. The global vaccine race has been punctuated, and to some degree deflated, by recent announcements of a ‘Sputnik-like’ moment out of Russia, where claims are that they have already approved a SARS-CoV-2 vaccine. But do you do moonshots if they’re not safe? What if they’re effective?

Click Here For Complete Article Text

• Biotechnology

• Contract Pharma

• 9/9/2020

• Article